Molecular Probe Precursor for Pancreatic Islet Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecular probes, such as 125I-labeled exendin(9-39), are ineffective for noninvasive three-dimensional imaging of pancreatic islets, making it difficult to detect and quantify pancreatic islets noninvasively, which is crucial for early diabetes diagnosis and prevention.
Innovation Solution
A molecular probe is developed by labeling the amino group at the N-terminus of a precursor polypeptide with a positron emission or single photon emission nuclide, specifically designed to bind to pancreatic islets, allowing for noninvasive three-dimensional imaging using positron emission tomography (PET).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional molecular probes (e.g., 125I-labeled exendin(9-39)) are used for imaging pancreatic islets, then the imaging can be performed, but noninvasive three-dimensional imaging is not achieved and quantification is difficult
Solution Approach 1:
The patent changes the labeling method from conventional 125I labeling to positron emission nuclide labeling (e.g., 11C, 18F, 62Cu, 64Cu, 89Sr, 90Y), which fundamentally alters the imaging modality from planar to three-dimensional PET imaging, enabling both noninvasive imaging and precise quantification
Solution Approach 2:
The patent replaces the conventional gamma camera imaging system with a PET imaging system that uses positron emission nuclides, substituting the detection mechanism to achieve superior three-dimensional imaging capability and quantification accuracy
2Loss of time
If early detection of pancreatic islet decrease is achieved, then diabetes prevention becomes possible, but current techniques cannot detect functional abnormalities at the appropriate early stage
Solution Approach 1:
The patent replaces indirect functional assessment methods with direct structural imaging of pancreatic islets using PET, enabling visualization and quantification of islet mass at the cellular level before functional abnormalities manifest
Solution Approach 2:
The patent changes the detection parameter from functional metrics (glucose tolerance) to structural metrics (islet mass and β-cell quantity), allowing detection of pathological changes at an earlier stage when interventions are most effective
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables noninvasive three-dimensional imaging and quantification of pancreatic islets, facilitating early detection and diagnosis of diabetes by determining the amount of pancreatic islets, thereby aiding in prevention and treatment.
Implementation Method 1
labeling the amino group at the N-terminus of a precursor with a positron emission nuclide or a single photon emission nuclide
Implementation Method 2
labeling the amino group at the N-terminus of a precursor with a positron emission nuclide or a single photon emission nuclide
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3B
AI summary
A precursor of a molecular probe for imaging of pancreatic islets is provided. The precursor includes a polypeptide represented by any one of the following formulae (1) to (12), or a polypeptide having a homology with the foregoing polypeptide: *-DLSKQMEEEAVRLFIEWLK* NGGPSSGAPPPS-NH2 (1) *-LSKQMEEEAVRLFIEWLK* NGGPSSGAPPPS-NH2 (2) *-SKQMEEEAVRLFIEWLK* NGGPSSGAPPPS-NH2 (3) *-KQMEEEAVRLFIEWLK* NGGPSSGAPPPS-NH2 (4) *-DLSK* QMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 (5) *-LSW QMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 (6) *-SK* QMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 (7) *-K* QMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 (8) DLSK* QMEEEAVRLFIEWLK* NGGPSSGAPPPS-NH2 (9) LSK* QMEEEAVRLFIEWLK* NGGPSSGAPPPS-NH2 (10) SK* QMEEEAVRLFIEWLK* NGGPSSGAPPPS-NH2 (11) K* QMEEEAVRLFIEWLK* NGGPSSGAPPPS-NH2 (12)